Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/79734
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pyragius, C. | - |
dc.contributor.author | Fuller, M. | - |
dc.contributor.author | Ricciardelli, C. | - |
dc.contributor.author | Oehler, M. | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | International Journal of Molecular Sciences, 2013; 14(4):7742-7756 | - |
dc.identifier.issn | 1422-0067 | - |
dc.identifier.issn | 1661-6596 | - |
dc.identifier.uri | http://hdl.handle.net/2440/79734 | - |
dc.description.abstract | Ovarian cancer remains the most lethal gynaecological cancer. A better understanding of the molecular pathogenesis of ovarian cancer is of critical importance to develop early detection tests and identify new therapeutic targets that would increase survival. Cancer cells depend on de novo lipid synthesis for the generation of fatty acids to meet the energy requirements for increased tumour growth. There is increasing evidence that lipid metabolism is deregulated in cancers, including ovarian cancer. The increased expression and activity of lipogenic enzymes is largely responsible for increased lipid synthesis, which is regulated by metabolic and oncogenic signalling pathways. This article reviews the latest knowledge on lipid metabolism and the alterations in the expression of lipogenic enzymes and downstream signalling pathways in ovarian cancer. Current developments for exploiting lipids as biomarkers for the detection of early stage ovarian cancer and therapeutic targets are discussed. Current research targeting lipogenic enzymes and lipids to increase the cytotoxicity of chemotherapy drugs is also highlighted. | - |
dc.description.statementofresponsibility | Carmen E. Pyragius, Maria Fuller, Carmela Ricciardelli and Martin K. Oehler | - |
dc.language.iso | en | - |
dc.publisher | Molecular Diversity Preservation International (MDPI) AG. | - |
dc.rights | © 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). | - |
dc.source.uri | http://dx.doi.org/10.3390/ijms14047742 | - |
dc.subject | ovarian cancer | - |
dc.subject | lipid synthesis | - |
dc.subject | signalling pathways | - |
dc.subject | biomarkers | - |
dc.subject | therapeutic targets | - |
dc.title | Aberrant lipid metabolism: an emerging diagnostic and therapeutic target in ovarian cancer | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.3390/ijms14047742 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Fuller, M. [0000-0001-9092-8942] | - |
dc.identifier.orcid | Ricciardelli, C. [0000-0001-7415-1854] | - |
dc.identifier.orcid | Oehler, M. [0000-0002-2651-5913] | - |
Appears in Collections: | Aurora harvest Obstetrics and Gynaecology publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
hdl_79734.pdf | Published version | 204.93 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.